间皮素作为癌症免疫治疗的生物标志物和治疗靶点
Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer.
癌症仍是一个关键的全球健康问题，原因在于发现晚、耐药和高死亡率。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
靶向间皮素的自体嵌合抗原受体巨噬细胞临床研究显示卵巢癌治疗中的安全性
英文原题：A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy.
查看英文原题
A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-巨噬细胞因其对肿瘤的高浸润性以及在吞噬作用和免疫调节中的双重作用，在治疗实体瘤方面具有广阔前景。本文展示了CAR-巨噬细胞治疗两例卵巢癌患者的临床结果。CAR-巨噬细胞是通过将靶向间皮素的CAR导入患者原代外周血单核细胞来源的巨噬细胞中制备的，并将产品经静脉输注给患者。我们的数据显示输注产品具有良好的安全性，疗效可进一步提高。在临床前模型中，腹腔内输注CAR-巨噬细胞已被证明可有效治疗腹腔内肿瘤，为展示CAR-巨噬细胞治疗腹腔内肿瘤的概念验证性临床疗效铺平了道路。
展开英文摘要原文
CAR-macrophage has promising prospect in treating solid tumors, due to its high infiltration into tumors, and its dual roles in phagocytosis and immune modulation.
Here we show the clinical results of CAR-macrophage treatment of two ovarian cancer patients. The CAR-macrophages were produced by introducing a mesothelin targeting CAR to patients' primary peripheral blood mononuclear cell-derived macrophages, and the products were infused to patients intravenously.
Our data show good safety of the infusion product, and the efficacy can be further improved. Intraperitoneal infusion of CAR-macrophages has proven effective in treating intraperitoneal tumors in a preclinical model, paving the way for demonstrating proof-of-concept clinical efficacy of CAR-macrophages in the treatment of intraperitoneal tumors.
论文信息
- 作者
- Li X、Wang X、Wang H、Zuo D、Xu J、Feng Y、Xue D、Zhang L
- 第一作者单位
- The First Department of Gynecological Oncology, Linyi Cancer Hospital, Linyi, 276002, China. Lyzlyylxm@163.com.China
- 通讯作者单位
- Liangzhu Laboratory, Zhejiang University, Hangzhou, 311121, China. zhgene@zju.edu.cn.China
- 文献类型
- 读者来信
- 期刊
- Journal of hematology & oncology2024 Nov 28
- 原文标识
- PubMed 39609867 · DOI 10.1186/s13045-024-01635-5
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →